GLGeovana S. F. Leite

Geovana S. F. Leite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Geovana S. F. Leite has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Potential Benefits Of Exercise-mobilized Donor Lymphocyte Infusion Combined With Abatacept In A Xenogeneic Leukemia Model

    by Geovana S.F. Leite, Matina Kounelis, Richard J. Simpson, Emmanuel Katsanis

    Was not provided for this article.

  • Open Access

    Probiotic Supplementation Can Alter Inflammation Parameters and Self-Reported Sleep After a Marathon: A Randomized, Double-Blind, Placebo-Controlled Study

    by Valdir Aquino-Lemos, Geovana S. F. Leite, Edgar T. Silva, Helena A. P. Batatinha, Ayane S. Resende, Antônio H. Lancha-Junior, José C. R. Neto, Sergio Tufik, Ronaldo V. Thomatieli-Santos

    Background: Sleep is essential for athletes’ physical performance and recovery. However, strenuous exercise has the potential to increase inflammation and worsen sleep. This study evaluated the effect of probiotic supplementation on self-reported sleep quality, daytime sleepiness, and inflammatory profile 24 h after a marathon. Methods: 27 marathon male runners were divided into the Probiotic group (Probiotic n = 14) or the Placebo group (Placebo n = 13). The Probiotic group consumed 1 × 1010 CFU of Lactobacillus acidophilus, 1 × 1010 CFU of Bifidobacterium lactis + 5 g/day maltodextrin for 30 days prior to the marathon. The Placebo group received a sachet of 5 g/day maltodextrin during the same period. Sleep and inflammatory status were assessed before supplementation, before the marathon, and 1 h and 24 h after the marathon. Data were analyzed using Statistic 13.3 and expressed as mean ± standard deviation. Tukey’s post hoc test was followed by a two-way ANOVA with repeated measures. The level of significance was set at p ≤ 0.05. Results: In the Placebo group, daytime sleepiness, sleep latency, and global sleep score increased 24 h after the marathon, while total sleep time and sleep efficiency decreased. In the Probiotic group, daytime sleepiness, sleep latency, and global sleep scores were lower 24 h after the marathon compared to the Placebo group. Total sleep time and sleep efficiency were higher in the Probiotic group compared to the Placebo group 24 h after the marathon. IL-1β and TNF-α concentrations decreased compared to Basal in both groups. IL-1β levels were lower 24 h after treatment compared to pre-treatment in the Placebo group. IL-6 was lower 24 h after the marathon in both groups. LPS concentrations were lower 1 h and 24 h after the marathon in the Probiotic group compared to the Basal group. There was no difference in cytokines and LPS between the groups. Conclusions: Supplementation with Lactobacillus acidophilus and Bifidobacterium lactis for 30 days changes self-reported sleep and reduces LPS concentration after the marathon.


  • Open Access

    A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo

    by Dimitrios Filioglou, Nina Santa-Cruz, Geovana S. F. Leite, Dan W. Davini, Megan J. Cracchiolo, Forrest L. Baker, Muhammad Husnain, Richard J. Simpson, Vasilios Voudouris, Emmanuel Katsanis

    Background/Objectives: Bendamustine (BEN) combined with rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formulation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we investigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 inhibitor Venetoclax (VEN) and/or the oral BTKi Acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. Methods: We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. For the in vivo studies, all treatments were administered via oral gavage in xenograft mouse models. Therapeutic efficacy was evaluated by monitoring tumor growth and survival. Results: BEN induced significant cytotoxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrated limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Conclusions: Our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.


  • Open Access

    A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma in Vitro and in Vivo.

    by Dimitrios Filioglou, Nina Santa-Cruz, Geovana Sf Leite, Dan W Davini, Megan J Cracchiolo, Forrest L Baker, Muhammad Husnain, Richard J Simpson, Vasilios Voudouris, Emmanuel Katsanis

    Bendamustine (BEN) combined with Rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formu-lation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we in-vestigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 in-hibitor Venetoclax (VEN) and/or the oral BTKi acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. BEN induced significant cyto-toxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrat-ed limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Overall, our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.